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Background
Cervical cancer is the second most common gynecologic
malignant tumor, and is frequently associated with human
papilloma virus (HPV) infection. Patients with vascular
invaded tumors are more likely to develop metastatic dis-
ease after radical resection of primary tumor. Current
treatment for metastatic cervical cancer is not effective. In
2011, a patient was diagnosed as HPV+ cervical squamous
cell carcinoma with vascular invasion. 33 months after
radical resection, and subsequent adjuvant chemoradiation
therapy, metastasis was detected on the right sacroiliac
joint. Given that standard therapy was unsuccessful, the
patient was treated with MASCT (Multiple Antigen Sti-
mulating Cellular Therapy), which is composed of multi-
ple tumor antigen pulsed dendritic cells (DCs) and
autologous T lymphocytes activated by these DCs.
Methods
Monocytes from the patient’s PBMCs were differentiated
into immature dendritic cells (iDCs) and then pulsed with
multiple synthetic peptide antigens including tumor-asso-
ciated antigens and HPV specific antigens. The semi-mature
DCs were further stimulated by diverse TLR ligands to dif-
ferentiate into mature DCs (mDCs). Half of these mDCs
were subcutaneous injected to the patient, and the other
half were co-cultured with the maintaining non-adherent
T cells for another 7-9 days before infusion back to
the patient.
Results
The mDCs expressed high level of HLA-DR, CD80, CD86,
CD83, and CCR7 on the surface. And the activated T cells
were almost exclusively CD3+ T cells, with a major part
being CD3+CD8+ cells and insignificant amounts of regu-
latory T cells. After local irradiation, the patient was given
repeating MASCT treatments every 1-2 months. After 3
times MASCT treatments (6 months after metastasis), the
patient was evaluated as partial remission by whole body
bone SPECT (single-photon emission computed tomogra-
phy). Following additional 5 times MASCT treatments (12
months after metastasis), the patient remained partial
remission. Moreover, specific responses against tumor
antigens were detected in the patients’ PBMCs by IFNg
ELISPOT assay, such as telomerase, p53, CEA, and
HPV18/58 (Figure 1). Based on patient’s specific immune
response, we therefore adjusted her antigen peptide pool
by saving the antigens, which had induced specific
responses and removed the peptides that did not. The
adjusted antigen pool clearly further boosted the specific
responses (Figure 2).
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Conclusion
Our study provides MASCT with as a safe treatment,
which has reduced the metastasis of the cervical cancer
patient. Moreover, tumor antigens specific T cell
responses could be robustly raised in cervical cancer
patients after MASCT treatment, and were even further
boosted after patient-specific antigens selection.
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